Precision Biosciences (DTIL) Current Assets (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Current Assets of $108.7 million for Q1 2026, up 32.39% year-over-year from $82.1 million in Q1 2025, and down 8.46% quarter-over-quarter from $118.7 million in Q4 2025.
Precision Biosciences (DTIL) Current Assets (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Current Assets for 9 consecutive years, with $108.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 32.39% year-over-year to $108.7 million; the TTM figure through Mar 2026 stood at $108.7 million (up 32.39% YoY), while the FY2025 annual figure was $118.7 million, up 25.0% from the prior year.
- Current Assets eased to $108.7 million in Q1 2026 per DTIL's latest filing, from $118.7 million in the prior quarter.
- Across five years, Current Assets topped out at $247.7 million in Q2 2022 and bottomed at $51.7 million in Q3 2025.
- Historically, Current Assets has averaged $138.1 million across 5 years, with a median of $136.4 million in 2023.
- Annual changes were most pronounced in 2025 — Current Assets tumbled 53.22% — and 2026, when it jumped 32.39%.
- Precision Biosciences' Current Assets stood at $199.1 million in 2022, then tumbled by 31.51% to $136.4 million in 2023, then plunged by 30.34% to $95.0 million in 2024, then increased by 25.0% to $118.7 million in 2025, then slipped by 8.46% to $108.7 million in 2026.
- Business Quant data shows DTIL's Current Assets at $108.7 million in Q1 2026, $118.7 million in Q4 2025, and $51.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - | 1.76 Bn |
| 10 | Precision Biosciences | 224.82 Mn | 137.27 Mn | - | 91.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91.55 Mn |
| Mar 31, 2026 | 108.69 Mn |
| Dec 31, 2025 | 118.74 Mn |
| Sep 30, 2025 | 51.71 Mn |
| Jun 30, 2025 | 70.26 Mn |
| Mar 31, 2025 | 82.10 Mn |
| Dec 31, 2024 | 94.99 Mn |
| Sep 30, 2024 | 110.52 Mn |
| Jun 30, 2024 | 144.04 Mn |
| Mar 31, 2024 | 160.83 Mn |
| Dec 31, 2023 | 136.36 Mn |
| Sep 30, 2023 | 145.85 Mn |
| Jun 30, 2023 | 147.86 Mn |
| Mar 31, 2023 | 169.02 Mn |
| Dec 31, 2022 | 199.11 Mn |
| Sep 30, 2022 | 225.37 Mn |
| Jun 30, 2022 | 247.69 Mn |
| Mar 31, 2022 | 134.05 Mn |
| Dec 31, 2021 | 161.75 Mn |
| Sep 30, 2021 | 183.05 Mn |